Sung H, Ferlay J, Siegel RL, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
Huang DQ, Mathurin P, Cortez-Pinto H, Loomba R. Global epidemiology of alcohol-associated Cirrhosis and HCC: trends, projections and risk factors. Nat Rev Gastroenterol Hepatol. 2023;20(1):37–49.
Shin SW, Ahn KS, Kim SW, Kim TS, Kim YH, Kang KJ. Liver resection Versus local ablation therapies for Hepatocellular Carcinoma within the Milan Criteria: a systematic review and Meta-analysis. Ann Surg. 2021;273(4):656–66.
Zhu P, Liao W, Zhang WG, et al. A prospective study using propensity score matching to compare long-term survival outcomes after Robotic-assisted, laparoscopic, or Open Liver Resection for patients with BCLC stage 0-A Hepatocellular Carcinoma. Ann Surg. 2023;277(1):e103–11.
Lin K, Huang Q, Wang L, et al. Pre- and postoperative models for prediction of recurrence in Non-B, Non-C Hepatocellular Carcinoma. Front Oncol. 2021;11:612588.
Article CAS PubMed PubMed Central Google Scholar
Yang P, Qiu J, Li J, et al. Nomograms for pre- and postoperative prediction of long-term survival for patients who underwent Hepatectomy for multiple Hepatocellular Carcinomas. Ann Surg. 2016;263(4):778–86.
Li J, Zhou J, Yang PH, et al. Nomograms for survival prediction in patients undergoing liver resection for Hepatitis B virus related early stage hepatocellular carcinoma. Eur J Cancer. 2016;62:86–95.
Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–93.
Sun HC, Zhou J, Wang Z, et al. Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition). Hepatobiliary Surg Nutr. 2022;11(2):227–52.
Article PubMed PubMed Central Google Scholar
Wei WX, Yang ZS, Lu LH, et al. Long-term survival after partial hepatectomy for sub-stage patients with intermediate stage hepatocellular carcinoma. Int J Surg. 2018;56:256–63.
Sanghera C, Teh JJ, Pinato DJ. The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinoma. Liver Int. 2019;39(11):2008–23.
Wang Y, Peng C, Cheng Z, et al. The prognostic significance of preoperative neutrophil-lymphocyte ratio in patients with hepatocellular carcinoma receiving hepatectomy: a systematic review and meta-analysis. Int J Surg. 2018;55:73–80.
Okamura Y, Sugiura T, Ito T, et al. Neutrophil to lymphocyte ratio as an indicator of the malignant behaviour of hepatocellular carcinoma. Br J Surg. 2016;103(7):891–8.
Article CAS PubMed Google Scholar
Toyoda H, Kumada T, Tada T, Sone Y, Kaneoka Y, Maeda A. Tumor markers for Hepatocellular Carcinoma: simple and significant predictors of Outcome in patients with HCC. Liver Cancer. 2015;4(2):126–36.
Article CAS PubMed PubMed Central Google Scholar
Marrero JA, Feng Z, Wang Y, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009;137(1):110–8.
Article CAS PubMed Google Scholar
Sieghart W, Pinter M, Hucke F, et al. Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma. Hepatology. 2013;57(6):2224–34.
Article CAS PubMed Google Scholar
Nakanishi H, Kurosaki M, Tsuchiya K, et al. Novel pretreatment scoring incorporating C-reactive protein to predict overall survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment. Liver Cancer. 2016;5(4):257–68.
Article CAS PubMed PubMed Central Google Scholar
Nagaoka S, Yoshida T, Akiyoshi J, et al. Serum C-reactive protein levels predict survival in hepatocellular carcinoma. Liver Int. 2007;27(8):1091–7.
Article CAS PubMed Google Scholar
Kelley RK, Meyer T, Rimassa L, et al. Serum alpha-fetoprotein levels and clinical outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res. 2020;26(18):4795–804.
Article CAS PubMed PubMed Central Google Scholar
Notarpaolo A, Layese R, Magistri P, et al. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related Cirrhosis who had received a liver transplant for HCC. J Hepatol. 2017;66(3):552–9.
Strasberg SM, Phillips C. Use and dissemination of the brisbane 2000 nomenclature of liver anatomy and resections. Ann Surg. 2013;257(3):377–82.
Tsilimigras DI, Hyer JM, Diaz A et al. Synergistic impact of alpha-fetoprotein and Tumor Burden on Long-Term outcomes following curative-intent resection of Hepatocellular Carcinoma. Cancers (Basel). 2021. 13(4).
Tsilimigras DI, Bagante F, Moris D, et al. Recurrence patterns and outcomes after resection of Hepatocellular Carcinoma within and beyond the Barcelona Clinic Liver Cancer Criteria. Ann Surg Oncol. 2020;27(7):2321–31.
Kudo M, Izumi N, Sakamoto M, et al. Survival analysis over 28 years of 173,378 patients with Hepatocellular Carcinoma in Japan. Liver Cancer. 2016;5(3):190–7.
Article PubMed PubMed Central Google Scholar
Montal R, Andreu-Oller C, Bassaganyas L, et al. Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials. Br J Cancer. 2019;121(4):340–3.
Article CAS PubMed PubMed Central Google Scholar
Scheiner B, Pomej K, Kirstein MM, et al. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score. J Hepatol. 2022;76(2):353–63.
Article CAS PubMed Google Scholar
Ji GW, Zhu FP, Xu Q, et al. Radiomic features at contrast-enhanced CT predict recurrence in early stage Hepatocellular Carcinoma: a multi-institutional study. Radiology. 2020;294(3):568–79.
Ji GW, Zhu FP, Xu Q, et al. Machine-learning analysis of contrast-enhanced CT radiomics predicts recurrence of hepatocellular carcinoma after resection: a multi-institutional study. EBioMedicine. 2019;50:156–65.
Article PubMed PubMed Central Google Scholar
Woo HG, Park ES, Cheon JH, et al. Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin Cancer Res. 2008;14(7):2056–64.
Wu C, Lin J, Weng Y, et al. Myeloid signature reveals immune contexture and predicts the prognosis of hepatocellular carcinoma. J Clin Invest. 2020;130(9):4679–93.
Article CAS PubMed PubMed Central Google Scholar
Villanueva A, Hoshida Y, Battiston C, et al. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology. 2011;140(5):1501–12e2.
Article CAS PubMed Google Scholar
Sun Y, Wu L, Zhong Y, et al. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. Cell. 2021;184(2):404–421e16.
Article CAS PubMed Google Scholar
Zeng J, Zeng J, Lin K, et al. Development of a machine learning model to predict early recurrence for hepatocellular carcinoma after curative resection. Hepatobiliary Surg Nutr. 2022;11(2):176–87.
Article PubMed PubMed Central Google Scholar
Daniele B, Bencivenga A, Megna AS, Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):108–12.
Richardson P, Duan Z, Kramer J, Davila JA, Tyson GL, El-Serag HB. Determinants of serum alpha-fetoprotein levels in hepatitis C-infected patients. Clin Gastroenterol Hepatol. 2012;10(4):428–33.
Article CAS PubMed Google Scholar
Jun CH, Ki HS, Lee KH, et al. Impact of serum C-reactive protein level on the prognosis of patients with hepatocellular carcinoma undergoing TACE. Clin Mol Hepatol. 2013;19(1):70–7.
Article PubMed PubMed Central Google Scholar
Socha MW, Malinowski B, Puk O, et al. C-reactive protein as a diagnostic and prognostic factor of endometrial cancer. Crit Rev Oncol Hematol. 2021;164:103419.
Dufour JF. C-reactive protein, a prognostic marker in hepatocellular carcinoma. Hepatology. 2013;57(6):2103–5.
Article CAS PubMed Google Scholar
Huang J, Baum Y, Alemozaffar M, et al. C-reactive protein in urologic cancers. Mol Aspects Med. 2015;45:28–36.
Comments (0)